OBJECTIVES To review the oncologic outcomes of laparoscopic renal cryoablation (LRC) for small renal masses (SRMs) < 4 cm. METHODS The present study was an observational, retrospective analysis of LRC in 123 patients. The indications for LRC were solid SRMs of the kidney < 4 cm in diameter diagnosed on preoperative computed tomography or magnetic resonance imaging as an enhancing mass. Follow-up was determined using magnetic resonance imaging. Local recurrence after LRC was defined as an enlarging or persistently enhancing treatment site on follow-up imaging. RESULTS A total of 131 SRMs in 123 patients (91 men and 32 women) were treated from September 2000 to June 2008. The mean tumor size was 2.14 +/- 0.86 cm (range 0.5-4). Biopsy cores from the 123 patients revealed clear cell renal cell carcinoma (RCC) in 69 patients (56.1%), papillary RCC in 8 (6.53%), chromophobe RCC in 3 (2.4%), mucinous, tubular, and spindle RCC in 1 (0.8%), oncocytoma in 27 (21.9%), angiomyolipoma in 5 (4.1%), and xanthogranulomatous pyelonephritis in 1 patient (0.8%). The biopsy findings were nondiagnostic (fibrotic/necrotic tissue) in 9 cases (7.3%). The mean follow-up was 46.04 +/- 25.75 months (median 41, range 12-96). In 44 patients with RCC and a mean follow-up of 61.3 +/- 13.76 months, the cancer-specific survival rate was 100% and the overall survival rate was 93.2%. None of the 53 patients (RCC plus those with nonmalignant lesions) who had follow-up > 5 years developed radiographic recurrence. CONCLUSIONS Our findings have confirmed that LRC can be considered a safe and intermediate-term effective method to treat SRMs. UROLOGY 76: 624-630, 2010. (c) 2010 Elsevier Inc.

Oncologic Results of Laparoscopic Renal Cryoablation for Clinical T1a Tumors: 8 Years of Experience in a Single Institution

MONTORSI , FRANCESCO;
2010-01-01

Abstract

OBJECTIVES To review the oncologic outcomes of laparoscopic renal cryoablation (LRC) for small renal masses (SRMs) < 4 cm. METHODS The present study was an observational, retrospective analysis of LRC in 123 patients. The indications for LRC were solid SRMs of the kidney < 4 cm in diameter diagnosed on preoperative computed tomography or magnetic resonance imaging as an enhancing mass. Follow-up was determined using magnetic resonance imaging. Local recurrence after LRC was defined as an enlarging or persistently enhancing treatment site on follow-up imaging. RESULTS A total of 131 SRMs in 123 patients (91 men and 32 women) were treated from September 2000 to June 2008. The mean tumor size was 2.14 +/- 0.86 cm (range 0.5-4). Biopsy cores from the 123 patients revealed clear cell renal cell carcinoma (RCC) in 69 patients (56.1%), papillary RCC in 8 (6.53%), chromophobe RCC in 3 (2.4%), mucinous, tubular, and spindle RCC in 1 (0.8%), oncocytoma in 27 (21.9%), angiomyolipoma in 5 (4.1%), and xanthogranulomatous pyelonephritis in 1 patient (0.8%). The biopsy findings were nondiagnostic (fibrotic/necrotic tissue) in 9 cases (7.3%). The mean follow-up was 46.04 +/- 25.75 months (median 41, range 12-96). In 44 patients with RCC and a mean follow-up of 61.3 +/- 13.76 months, the cancer-specific survival rate was 100% and the overall survival rate was 93.2%. None of the 53 patients (RCC plus those with nonmalignant lesions) who had follow-up > 5 years developed radiographic recurrence. CONCLUSIONS Our findings have confirmed that LRC can be considered a safe and intermediate-term effective method to treat SRMs. UROLOGY 76: 624-630, 2010. (c) 2010 Elsevier Inc.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/2562
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 59
  • ???jsp.display-item.citation.isi??? 56
social impact